Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-27
2009-10-13
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S127000, C548S121000
Reexamination Certificate
active
07601744
ABSTRACT:
The present invention is directed to benzothiadiazolylphenylalkylamine derivatives of formula I:or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
REFERENCES:
patent: 99/44601 (1999-09-01), None
patent: 2004/043903 (2004-05-01), None
patent: 2005/037207 (2005-04-01), None
Ashton et al. Journal of Sex & Marital Therapy, vol. 23 (3), 1997, pp. 165-175, Abstract only.
U.S. Appl. No. 11/529,441, filed Sep. 27, 2006, Mahaney et al.
U.S. Appl. No. 11/529,450, filed Sep. 27, 2006, McComas et al.
Berendsen, H. H. G., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European Journal of Pharmacology, 2001, 419(1), 47-54.
Berendsen, H. H. G., “The role of serotonin in hot flushes,”Maturitas, 2000, 36(3), 155-164.
Bundgaard, H. (ed.),Design of Prodrugs, Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4), 285-298.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Eliel, E. L.,Stereochemistry of Carbon Compounds, McGraw Hill, NY (1962) Ch. 4, pp. 46-87.
Fink, G. et al., “Oestrogen and mental state,”Nature, 1996, 383(6598), 306.
Freedman, R. R. et al., “Clonidine raises the sweating threshold in symptomatic but not asymptomatic postmenopausal women,”Fertility&Sterility, 2000, 74(1), 20-3.
French, N., “α2-Adrenoceptors and I2sites in the mammalian central nervous system,”Pharmacol. Ther., 1995, 68(2), 175-208.
Greene, T.W. and Wuts, P.G.M.,Protective Groups in Organic Synthesis2d. Ed., Wiley & Sons, 1991, Ch. 2 (pp. 10-142), Ch. 5 (pp. 224-276), and Ch. 7 (pp. 309-405).
Higuchi and Stella (eds.),Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975), pp. 1-115 and 196-223.
Hughes, David L., “Progress in the Mitsunobu Reaction. A Review,”Organic Preparations and Procedures International, 1996, 28(2), 127-164.
Jacques, J. et al.,Enantiomers, Racemates and Resolutions, Wiley Interscience, NY (1981) pp. 251-434.
Janowsky, D. S. et al., “Desipramine: an overview,”Journal of Clinical Psychiatry, 1984, 45(10 Pt 2), 3-9.
Katovich, M. J. et al., “Mechanisms Mediating the Thermal Response to Morphine Withdrawal in Rats,”Proceedings of the Society for Experimental Biology&Medicine, 1990, 193(2), 129-35.
Krämer, P. et al., “Prevention of Hot Flushes with CPA in the Hormonal Treatment of Prostatic Cancer Results of a Placebo-Controlled Double-Blind Trial,”3rd Int'l Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment-Proceedings, Paris, France: SCI, 3-7 1992.
Krogsgaard-Larsen, et al., (ed).Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191, 1991.
Kronenberg, F. et al., “Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,”Can. J. Physiol. Pharmacol., 1987, 65, 1312-1324.
Loprinzi, C.L. et al., “Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial,”Lancet, Dec. 16, 2000, 356(9247), 2059-2063.
Mackinnon et al., “α2-Adrenoceptors: more subtypes but fewer functional differences,”TIPS, 1994, 15, 119-123.
Merchenthaler et al., “The effect of estrogens and antiestrogens in a rat model for hot flush,”Maturitas, 1998, 30(3), 307-316.
Pacholczyk, T. et al., “Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter,”Nature, 1991, 350(6316), 350-354.
Panek, D.U. et al., “Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions,”J. Pharmacol. Exp. Ther., 1986, 236(3), 646-652.
Prasad, P.D., et al., “Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells,”Placenta, 1996, 17(4), 201-7.
Remington 's Pharmaceutical Sciences, 17thEd., Gennaro, A. R. (Ed.), Mack Publishing Company, Easton, PA (1985) pp. 1409-1677.
Sharpless, et. al., “Asymmetric Epoxidation of Allyl Alcohol: Efficient Routes to Homochiral β-Adrenergic Blocking Agents,”J. Org. Chem. 1986, 51, 3710-3712.
Stearns,V. et al., “Paroxetine controlled release in the treatment of menopausal hot flashes,”JAMA, 2003, 289:2827-2834.
Waldinger et al., “Treatment of hot flushes with mirtazapine: four case reports,”Maturitas, 2000, 36(3), 165-168.
Widder, et al. (ed.),Methods in Enzymology, vol. 112, Academic Press (1985), pp. 309-323.
Wilen, S.H.Tables of Resolving Agents and Optical Resolutions, pp. 268-298, E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972.
Wilen, S.H., et al., “Strategies in optical resolutions,”Tetrahedron, 33, 2725-2736, 1977.
McComas Casey Cameron
Terefenko Eugene Anthony
Trybulski Eugene John
Vu An Thien
Zhang Puwen
Chu Yong
Ene Doina G.
Joran A. David
Kurlandsky David R.
Wyeth
LandOfFree
Benzothiadiazolylphenylalkylamine derivatives and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzothiadiazolylphenylalkylamine derivatives and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiadiazolylphenylalkylamine derivatives and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133677